Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

David L. DeRemer, Celalettin Ustun, Kavita Natarajan

Research output: Contribution to journalArticle

114 Scopus citations

Fingerprint Dive into the research topics of 'Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences